Is Circulating Tumor DNA Ready for Clinical Use in Large B-cell Lymphoma?
Blood Journal · 10.11.2026
DOI: 10.1182/blood.2026033073 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Journal, online erschienen am 10.11.2026. Verfasst von Reid W Merryman und 1 weiteren Autor:innen. Beteiligte Einrichtung: Dana Farber Cancer Institute, Boston, Massachusetts, United States.
Abstract (Originalsprache)
Response assessment after frontline therapy for large B-cell lymphoma risk-stratifies patients into those at low risk for relapse and those with residual disease. Positron emission tomography scans form the cornerstone of the response criteria but cannot detect molecular-only disease. Circulating tumor DNA detects measurable residual disease (MRD) after therapy which is emerging as an adjunct tool for complex clinical decision-making. We discuss how MRD after therapy can be clinically implemented and additional data needed to unlock its full potential.
Autor:innen und Institutionen
- Dana Farber Cancer Institute, Boston, Massachusetts, United States.
- Memorial Sloan Kettering Cancer Center, New York, New York, United States.
ORCID-Profile: Mark Roschewski
Zitieren
APA
Merryman, R. W., & Roschewski, M. (2026). Is Circulating Tumor DNA Ready for Clinical Use in Large B-cell Lymphoma?. Blood Journal. https://doi.org/10.1182/blood.2026033073
Vancouver
Merryman RW, Roschewski M. Is Circulating Tumor DNA Ready for Clinical Use in Large B-cell Lymphoma?. Blood Journal. 2026. doi:10.1182/blood.2026033073
BibTeX
@article{Merryman2026,
author = {Merryman, Reid W and Roschewski, Mark},
title = {Is Circulating Tumor DNA Ready for Clinical Use in Large B-cell Lymphoma?},
journal = {Blood Journal},
year = {2026},
doi = {10.1182/blood.2026033073}
}
EUVIMED